Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369703 · ClinicalTrials.gov registry record
Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 199
- Enrollment target
NCT04369703: Completed study, sponsored by Mayo Clinic.
NCT04369703 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 199 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04369703 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 199 participants
- Enrollment target
Study Summary
1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2022-04-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04369703
The ClinicalTrials.gov registry entry for NCT04369703 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04369703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04369703 about?
NCT04369703 is a clinical study titled "Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery". 1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access th...
What is the current status of trial NCT04369703?
This trial is currently completed. The enrollment target is 199 participants. The study started on 2020-01-28. Estimated completion is 2022-04-29.
Who is sponsoring clinical trial NCT04369703?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.